Melchior et al., 2003 - Google Patents
Ectopic expression of the TrkA receptor in adult dopaminergic mesencephalic neurons promotes retrograde axonal NGF transport and NGF-dependent …Melchior et al., 2003
View PDF- Document ID
- 6435936932148978580
- Author
- Melchior B
- Nerrière-Daguin V
- Laplaud D
- Rémy S
- Wiertlewski S
- Neveu I
- Naveilhan P
- Meakin S
- Brachet P
- Publication year
- Publication venue
- Experimental neurology
External Links
Snippet
A recombinant adeno-associated virus (rAAV) was used to investigate the impact of an ectopic expression of the NGF high-affinity receptor in adult neurons. The rat TrkA cDNA cloned in a pCMX vector was first tagged with a human c-Myc sequence. The resulting …
- 210000002569 neurons 0 title abstract description 86
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klein et al. | Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer | |
| Patel et al. | GDNF delivery for Parkinson’s disease | |
| Su et al. | Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys | |
| Allen et al. | GDNF, NGF and BDNF as therapeutic options for neurodegeneration | |
| Leone et al. | Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease | |
| Domanskyi et al. | Prospects of neurotrophic factors for Parkinson's disease: comparison of protein and gene therapy | |
| Gravel et al. | Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons | |
| Collier et al. | Therapeutic potential of nerve growth factors in Parkinson’s disease | |
| Connor et al. | The role of neuronal growth factors in neurodegenerative disorders of the human brain | |
| Lad et al. | Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease | |
| Hernandez-Chan et al. | Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson’s disease | |
| Liu et al. | Application of recombinant adenovirus for in vivo gene delivery to spinal cord | |
| Hollis II et al. | IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injury | |
| Tome et al. | Role of neurotrophic factors in Parkinson's disease | |
| Nagahara et al. | Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery | |
| EP2892567B1 (en) | Parkinson's disease treatment by bdnf-flag gene transfer through neurotensin polyplex to nigral dopamine neurons | |
| Chattopadhyay et al. | HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy | |
| Martinez-Fong et al. | NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease | |
| Kells et al. | Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain | |
| US20030118556A1 (en) | Targeted retrograde gene delivery to motor neurons | |
| US7674455B2 (en) | Targeted retrograde gene delivery to motor neurons | |
| Tuszynski et al. | Central infusions of brain-derived neurotrophic factor and neurotrophin-45, but not nerve growth factor and neurotrophin-3, prevent loss of the cholinergic phenotype in injured adult motor neurons | |
| Shen et al. | Recent progress in studies of neurotrophic factors and their clinical implications | |
| Bohn | A commentary on glial cell line-derived neurotrophic factor (GDNF): from a glial secreted molecule to gene therapy | |
| Alfonsetti et al. | Neurotrophic factor-based pharmacological approaches in neurological disorders |